SCHEMBL3070533

SCHEMBL3070533

O=C1Nc2c(ccc(F)c2F)C1(c1ccc(O)cc1)c1ccc(O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR55 Q9Y2T6 4/20 0.56
CNR1 P21554 3/20 0.56
HTT P42858 1/20 0.56
GPR35 Q9HC97 1/20 0.56
CHRM2 P08172 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
KCNH2 Q12809 1/20 0.50
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
PKM P14618 1/20 0.35
LMNA P02545 3/20 0.33
AKR1B1 P15121 1/20 0.33
MAPT P10636 3/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
XBP1 P17861 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
HTR6 P50406 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29385169 1.00 GPR55 (0.56) GPR55CNR1HTTGPR35CHRM2
SCHEMBL3192059 0.96 CNR1 (0.52) GPR55CNR1HTTGPR35CHRM2
SCHEMBL3092453 0.93 CNR1 (0.50) GPR55CNR1HTTGPR35CHRM2
SCHEMBL3190942 0.93 CNR1 (0.57) GPR55CNR1HTTGPR35CHRM2
SCHEMBL3093496 0.92 CNR1 (0.49) GPR55CNR1HTTGPR35CHRM2
SCHEMBL3202505 0.89 CNR1 (0.50) GPR55CNR1HTTGPR35CHRM2
SCHEMBL3096370 0.89 CNR1 (0.47) GPR55CNR1HTTGPR35CHRM2
SCHEMBL13145529 0.88 CNR1 (0.46) GPR55CNR1HTTGPR35CHRM2
SCHEMBL31184977 0.88 CNR1 (0.49) GPR55CNR1HTTGPR35CHRM2
SCHEMBL3076606 0.88 CNR1 (0.55) GPR55CNR1HTTGPR35CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20160106711-A1 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-04-21 US disclosed
US-20160106711-A1 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-04-21 US disclosed
WO-2014047437-A1 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-03-27 WO disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
US-20100029646-A1 PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS TOPO TARGET A/S (DK) 2010-02-04 US disclosed
US-20100029646-A1 PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS TOPO TARGET A/S (DK) 2010-02-04 US disclosed
US-20100029646-A1 PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS TOPO TARGET A/S (DK) 2010-02-04 US disclosed
EP-2102158-A1 PRODRUGS OF DIPHENYL OX- INDOL- 2 -ONE COMPOUNDS FOR THE TREATMENT OF CANCERS Topo Target A/S (DK) 2009-09-23 EP disclosed
WO-2008071387-A1 PRODRUGS OF DIPHENYL OX- INDOL- 2 -ONE COMPOUNDS FOR THE TREATMENT OF CANCERS TOPOTARGET A/S (DK) 2008-06-19 WO disclosed
WO-2008071387-A1 PRODRUGS OF DIPHENYL OX- INDOL- 2 -ONE COMPOUNDS FOR THE TREATMENT OF CANCERS TOPOTARGET A/S (DK) 2008-06-19 WO disclosed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 GPR55 2338/4885CNR1 973/4885HTT 1880/4885
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TPH2, TPH1, HTR2C GPR55 1842/4885CNR1 971/4885HTT 595/4885
US-20160106711-A1 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation RIOX2, EIF4A3, RPL35 GPR55 4125/4885CNR1 3719/4885HTT 347/4885
US-20100029646-A1 PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS IDO1, IDO2, TDO2 GPR55 2537/4885CNR1 597/4885HTT 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.